Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
Publication
, Other
Li, R; Sexton, WJ; Dhillon, J; Berglund, A; Naidu, S; Borjas, G; Rose, K; Kim, Y; Wang, X; Conejo-Garcia, JR; Jain, RK; Poch, MA; Spiess, PE ...
October 2, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, R., Sexton, W. J., Dhillon, J., Berglund, A., Naidu, S., Borjas, G., … Zhang, J. (2023). Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder. https://doi.org/10.1158/1078-0432.24228925
Li, Roger, Wade J. Sexton, Jasreman Dhillon, Anders Berglund, Shreyas Naidu, Gustavo Borjas, Kyle Rose, et al. “Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder,” October 2, 2023. https://doi.org/10.1158/1078-0432.24228925.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, et al. Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder. 2023.
Li, Roger, et al. Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder. 2 Oct. 2023. Crossref, doi:10.1158/1078-0432.24228925.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder. 2023.